Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Concurrent chemoradiotherapy with or without consolidation capecitabine plus cisplatin for locally advanced esophageal squamous cell carcinoma
ChiCTR1800017646Phase 3Not yet recruiting
- Sponsor
- Henan Cancer Hospital
- Start
- Jul 2018
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of capecitabine and cisplatin in Esophageal Squamous Cell Carcinoma (ESCC) (2 arms), sponsored by Henan Cancer Hospital. Primary endpoint: 2-year overall survival rate. Planned start Jul 2018; status: not yet recruiting.
02
Drugs
capecitabinecisplatin
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR1800017646.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800017646.